Sareum Announces New Drug Discovery Program
Posted on: Thursday, 6 March 2008, 09:01 CST
UK based Sareum Holdings has reported an additional in-house drug discovery program that targets the enzyme Fatty Acid Synthase or FASN.
High levels of FASN are present in most cancer types and are associated with diminished patient survival. Reduction of FASN activity has been reported to lead to cancer cell death and decreased tumor size in many different cancer models. Sareum has used its expertise in small molecule drug discovery to identify novel chemical compounds that inhibit the activity of FASN and show efficacy in cancer cell survival models. The company aims to develop these compounds into potential therapies for a wide range of cancers.
The company also filed patent applications for novel small molecule compounds that have been discovered to be effective against an important cancer drug discovery target.
Tim Mitchell, Sareum's CEO, said: "This program represent a significant development in Sareum's internal drug candidate portfolio with key assets identified against important cancer drug discovery targets. The development and ultimate commercialization of these programs is a key value driver for the company."
Source: Datamonitor
Related Articles
- Galapagos Acquires Structure-Based Drug Discovery From Sareum
- Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
- Research and Markets : Cancer Drug Discoveries: What the Future Holds: Breast Cancer Chapter
- Indivumed Announces New Product: Automated Immunohistochemistry Services for the Drug Discovery and Development Market
- Novelos Therapeutics to Present at MUSC Conference on Cancer Drug Discovery and Development
- Last Chance for Breakthrough Cancer Research Developments: 8th Annual Anti-Cancer Drug Discovery & Development Summit, July 17-18, 2006
- ProlX Pharmaceuticals Designated Corporate Partner in $5.6 Million Grant to Fund Targeted Therapy Cancer Drug Discovery Research
- Dyax Announces Cancer Lead at Drug Discovery Conference
- Genelabs Drug Discovery Team Advances Compounds Against the Hepatitis C Virus in Preclinical Development
 |
 |
User Comments (0)
RSS Feeds